Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension

Fernanda Pacella, Paolo Turchetti, Valentina Santamaria, David Impallara, Gianpaolo Smaldone, Chiara Brillante, Aloisa Librando, Angela Damiano, Jose Pecori-Giraldi, Elena PacellaDepartment of Sense Organs, University of Rome "Sapienza", Roma, ItalyBackground:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pacella F, Turchetti P, Santamaria V, Impallara D, Smaldone G, Brillante C, Librando A, Damiano A, Pecori-Giraldi J, Pacella E
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/f551e94c922c4fd6b03d2c12b01783eb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f551e94c922c4fd6b03d2c12b01783eb
record_format dspace
spelling oai:doaj.org-article:f551e94c922c4fd6b03d2c12b01783eb2021-12-02T05:36:48ZDifferential activity and clinical utility of latanoprost in glaucoma and ocular hypertension1177-54671177-5483https://doaj.org/article/f551e94c922c4fd6b03d2c12b01783eb2012-06-01T00:00:00Zhttp://www.dovepress.com/differential-activity-and-clinical-utility-of-latanoprost-in-glaucoma--a10031https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Fernanda Pacella, Paolo Turchetti, Valentina Santamaria, David Impallara, Gianpaolo Smaldone, Chiara Brillante, Aloisa Librando, Angela Damiano, Jose Pecori-Giraldi, Elena PacellaDepartment of Sense Organs, University of Rome "Sapienza", Roma, ItalyBackground: The purpose of this study was to demonstrate the hypotensive efficacy and tolerability of latanoprost when used as monotherapy and as polytherapy associated with antiglaucomatous medication proven to be ineffective in keeping intraocular pressure under control.Methods: Three hundred and thirty-seven patients (672 eyes) affected by primary open-angle glaucoma and intraocular hypertension were recruited over a period of 10 years from the Glaucoma Centre, Department of Ophthalmological Sciences, University of Rome "Sapienza", and treated, subject to informed consent, with latanoprost 0.005% alone or in combination with other ocular hypotensive drugs. The patients were followed during this period at regular intervals, with determination of visual field, fundus oculi, visual acuity, and eventual onset of local and systemic side effects.Results: Latanoprost used as monotherapy and as polytherapy renders possible optimal and durable control of intraocular pressure in the form of one antiglaucomatous drug because it can substitute for one or more drugs and obtain the same hypotensive effect.Conclusion: Latanoprost can be described as the ideal hypotensive drug, not only because of its ideal compliance profile (only one daily dose in the evening), excellent hypotensive effect, and, above all, few systemic side effects.Keywords: latanoprost, glaucoma, ocular hypertension, intraocular pressurePacella FTurchetti PSantamaria V, Impallara DSmaldone GBrillante CLibrando ADamiano APecori-Giraldi JPacella EDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 811-815 (2012)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Pacella F
Turchetti P
Santamaria V, Impallara D
Smaldone G
Brillante C
Librando A
Damiano A
Pecori-Giraldi J
Pacella E
Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
description Fernanda Pacella, Paolo Turchetti, Valentina Santamaria, David Impallara, Gianpaolo Smaldone, Chiara Brillante, Aloisa Librando, Angela Damiano, Jose Pecori-Giraldi, Elena PacellaDepartment of Sense Organs, University of Rome "Sapienza", Roma, ItalyBackground: The purpose of this study was to demonstrate the hypotensive efficacy and tolerability of latanoprost when used as monotherapy and as polytherapy associated with antiglaucomatous medication proven to be ineffective in keeping intraocular pressure under control.Methods: Three hundred and thirty-seven patients (672 eyes) affected by primary open-angle glaucoma and intraocular hypertension were recruited over a period of 10 years from the Glaucoma Centre, Department of Ophthalmological Sciences, University of Rome "Sapienza", and treated, subject to informed consent, with latanoprost 0.005% alone or in combination with other ocular hypotensive drugs. The patients were followed during this period at regular intervals, with determination of visual field, fundus oculi, visual acuity, and eventual onset of local and systemic side effects.Results: Latanoprost used as monotherapy and as polytherapy renders possible optimal and durable control of intraocular pressure in the form of one antiglaucomatous drug because it can substitute for one or more drugs and obtain the same hypotensive effect.Conclusion: Latanoprost can be described as the ideal hypotensive drug, not only because of its ideal compliance profile (only one daily dose in the evening), excellent hypotensive effect, and, above all, few systemic side effects.Keywords: latanoprost, glaucoma, ocular hypertension, intraocular pressure
format article
author Pacella F
Turchetti P
Santamaria V, Impallara D
Smaldone G
Brillante C
Librando A
Damiano A
Pecori-Giraldi J
Pacella E
author_facet Pacella F
Turchetti P
Santamaria V, Impallara D
Smaldone G
Brillante C
Librando A
Damiano A
Pecori-Giraldi J
Pacella E
author_sort Pacella F
title Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
title_short Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
title_full Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
title_fullStr Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
title_full_unstemmed Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
title_sort differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/f551e94c922c4fd6b03d2c12b01783eb
work_keys_str_mv AT pacellaf differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT turchettip differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT santamariavampnbspimpallarad differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT smaldoneg differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT brillantec differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT librandoa differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT damianoa differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT pecorigiraldij differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
AT pacellae differentialactivityandclinicalutilityoflatanoprostinglaucomaandocularhypertension
_version_ 1718400329516580864